Release form, composition and packing Betaserc
The tablets are round, flat, white or nearly white, with beveled edges, labeled "256" on one side and "S" over "∇" - on the other side of the tablet. 1 tab. betahistine dihydrochloride 8 mg. Excipients: microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal silicon dioxide, talc.
The tablets are round, biconvex, white or nearly white, with beveled edges, scored on one side and marked "267" on both sides of the risks and marked "S" over "∇" - on the other side of the tablet. 1 tab. betahistine dihydrochloride 16 mg. Excipients: microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal silicon dioxide, talc.
The tablets are round, biconvex, white or nearly white, with beveled edges, scored on one side and marked "289" on both sides of the risks and marked "S" over "∇" - on the other side of the tablet. 1 tab. betahistine dihydrochloride 24 mg. Excipients: microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal silicon dioxide, talc.
Clinico-pharmacological group: drug improving the microcirculation of the labyrinth that is used in the pathology of the vestibular apparatus.
Pharmacological action
Synthetic analogue of histamine. Acts primarily on the histamine H1-and H3-receptors of the inner ear and vestibular nuclei of the CNS. By direct agonistic effects on histamine H1-receptors in blood vessels of the inner ear, as well as indirectly through effects on the histamine H3-receptors improves microcirculation and capillary permeability of the inner ear, normalizes blood pressure of the endolymph in the labyrinth and cochlea.
Along with that betahistine increases blood flow in the basilar artery. Betaserc also has a strong central effect, as an inhibitor of histamine H3-receptors of the vestibular nerve nuclei. Normalizes conduction in neurons of the vestibular nuclei at the brainstem.
Clinical manifestations of these properties are to reduce the frequency and intensity of vertigo, noise reduction and tinnitus, improvement of hearing in the case of his slides.
Pharmacokinetics
Absorption and distribution
After oral betahistine dihydrochloride rapidly and almost completely absorbed from the gastrointestinal tract. Cmax in plasma is reached after 3 h. Plasma protein binding is low.
Breeding
T1 / 2 of 3-4 hours almost completely excreted by the kidneys as metabolites (2-peridiluksusnoy acid) for 24 h.
Statement
treatment and prophylaxis of vestibular vertigo of various origins;
syndromes characterized by dizziness, headache, tinnitus, progressive hearing loss, nausea and vomiting;
disease and Meniere's syndrome.
Dosing regimen
Drug is prescribed inside during the meal. Improving the condition stated in the beginning of therapy. Stable therapeutic effect is achieved within 2 weeks of Betaserc and can grow while taking the drug for several months.
Treatment of long-term. Duration of therapy set individually.
Side effect
Probably: violations of the gastrointestinal tract. In very rare cases: cutaneous manifestations of allergic reactions (skin rash, itching, hives), angioedema.
Contraindications
hypersensitivity to the drug.
Pregnancy and lactation
Insufficient data to assess the impact of the drug during pregnancy and lactation.
Use in hepatic dysfunction
Cautions
Precautions should be prescribed the drug to patients with gastric ulcer or duodenal ulcer history. During treatment, patients with pheochromocytoma and asthma should be under medical supervision.
Effects on ability to drive vehicles and management mechanisms
Betaserc has no sedative effect and does not affect ability to drive vehicles or operate machinery.
Overdose
Symptoms: nausea, vomiting at a dose of 728 mg, there were reports about the appearance of convulsions.
Treatment: symptomatic therapy.
Drug Interactions
Drug interactions drug Betaserc with other drugs has not been described. Incompatibilities are unknown.
Conditions and terms of
The drug should be stored in a dry place inaccessible to children at or above 25 ° C. Shelf life - 5 years.
The tablets are round, flat, white or nearly white, with beveled edges, labeled "256" on one side and "S" over "∇" - on the other side of the tablet. 1 tab. betahistine dihydrochloride 8 mg. Excipients: microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal silicon dioxide, talc.
The tablets are round, biconvex, white or nearly white, with beveled edges, scored on one side and marked "267" on both sides of the risks and marked "S" over "∇" - on the other side of the tablet. 1 tab. betahistine dihydrochloride 16 mg. Excipients: microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal silicon dioxide, talc.
The tablets are round, biconvex, white or nearly white, with beveled edges, scored on one side and marked "289" on both sides of the risks and marked "S" over "∇" - on the other side of the tablet. 1 tab. betahistine dihydrochloride 24 mg. Excipients: microcrystalline cellulose, mannitol, citric acid monohydrate, colloidal silicon dioxide, talc.
Clinico-pharmacological group: drug improving the microcirculation of the labyrinth that is used in the pathology of the vestibular apparatus.
Pharmacological action
Synthetic analogue of histamine. Acts primarily on the histamine H1-and H3-receptors of the inner ear and vestibular nuclei of the CNS. By direct agonistic effects on histamine H1-receptors in blood vessels of the inner ear, as well as indirectly through effects on the histamine H3-receptors improves microcirculation and capillary permeability of the inner ear, normalizes blood pressure of the endolymph in the labyrinth and cochlea.
Along with that betahistine increases blood flow in the basilar artery. Betaserc also has a strong central effect, as an inhibitor of histamine H3-receptors of the vestibular nerve nuclei. Normalizes conduction in neurons of the vestibular nuclei at the brainstem.
Clinical manifestations of these properties are to reduce the frequency and intensity of vertigo, noise reduction and tinnitus, improvement of hearing in the case of his slides.
Pharmacokinetics
Absorption and distribution
After oral betahistine dihydrochloride rapidly and almost completely absorbed from the gastrointestinal tract. Cmax in plasma is reached after 3 h. Plasma protein binding is low.
Breeding
T1 / 2 of 3-4 hours almost completely excreted by the kidneys as metabolites (2-peridiluksusnoy acid) for 24 h.
Statement
treatment and prophylaxis of vestibular vertigo of various origins;
syndromes characterized by dizziness, headache, tinnitus, progressive hearing loss, nausea and vomiting;
disease and Meniere's syndrome.
Dosing regimen
Drug is prescribed inside during the meal. Improving the condition stated in the beginning of therapy. Stable therapeutic effect is achieved within 2 weeks of Betaserc and can grow while taking the drug for several months.
Treatment of long-term. Duration of therapy set individually.
Side effect
Probably: violations of the gastrointestinal tract. In very rare cases: cutaneous manifestations of allergic reactions (skin rash, itching, hives), angioedema.
Contraindications
hypersensitivity to the drug.
Pregnancy and lactation
Insufficient data to assess the impact of the drug during pregnancy and lactation.
Use in hepatic dysfunction
Cautions
Precautions should be prescribed the drug to patients with gastric ulcer or duodenal ulcer history. During treatment, patients with pheochromocytoma and asthma should be under medical supervision.
Effects on ability to drive vehicles and management mechanisms
Betaserc has no sedative effect and does not affect ability to drive vehicles or operate machinery.
Overdose
Symptoms: nausea, vomiting at a dose of 728 mg, there were reports about the appearance of convulsions.
Treatment: symptomatic therapy.
Drug Interactions
Drug interactions drug Betaserc with other drugs has not been described. Incompatibilities are unknown.
Conditions and terms of
The drug should be stored in a dry place inaccessible to children at or above 25 ° C. Shelf life - 5 years.
No comments:
Post a Comment